Development of novel cancer therapy of targeting cancer-associated fibroblasts
| Project/Area Number |
24791423
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Keywords | がん微小環境 / 癌関連線維芽細胞 / 食道癌 / 光線免疫療法 / 消化器癌 / 近赤外線 |
|---|
| Research Abstract |
Cancer progression is closely related to fibroblasts. Normal fibroblasts change their phenotype to active form, cancer-associated fibroblasts (CAF) when they face on cancer cell and are effected. We have developed the new strategy, targeting of the CAF in cancer therapy. We focused on fibroblast activation protein and developed photoimmunotherapy (PIT) targeting FAP protein to kill activated fibroblasts, which is expressed in the cytoplasm and cell surface only when they are activated. The developed antibody was anti-FAP-IR700dye. Once the antibody attaches to targeted protein with IR700 and is irradiated by near-infrared light, the targeted cell was induced apoptosis by destroyed cell wall. In vitro and vivo assay, CAF cell promoted esophageal cancer progression. When we irradiated on those co-culture models with anti-FAP-IR700dye, in success cancer progression was suppressed dramatically.
|
Report
(3 results)
Research Products
(10 results)
